Live
FierceBiotechHarbinger Health raises $100M for new suite of blood-based cancer detection testsFierceBiotechAlamar Biosciences files for IPO amid opening life sciences funding windowEndpoints NewsParker Institute doubles down on cancer vaccines as part of ongoing rebootEndpoints NewsFDA approves Travere's Filspari as first drug for the kidney disease FSGSFierceBiotechBoehringer, Amgen discard early immunology candidates over lack of clinical potentialeLifeEnhanced bacterial chemotaxis in confined microchannels occurs at lane widths matching circular swimming radiuseLifeFear conditioning biases olfactory sensory neuron frequencies across generationseLifeSynaptotagmin 1 and Synaptotagmin 7 promote MR1-mediated presentation of <i>Mycobacterium tuberculosis</i> antigenseLifeKinesin-1 conformational dynamics are controlled by a cargo-sensitive TPR switcheLifeRevealing global stoichiometry conservation architecture in cells from Raman spectral patternsIlluminaIllumina Inc. stock outperforms competitors on strong trading day - MarketWatchThermo FisherThermo Fisher Scientific Inc (TMO) Shares Surge 3.6% -- What GF Score of 88 Tells Investors - GuruFocus
FierceBiotech Apr 14, 2026

Boehringer, Amgen discard early immunology candidates over lack of clinical potential

Boehringer, Amgen discard early immunology candidates over lack of clinical potential

Original
Body unavailable. Use the original source.

Directory

59 All